Author/Authors :
Zolghadri, Samaneh Radiopharmaceutical Research & Development Laboratory (RRDL) - Nuclear Science and Technology Research Institute (NSTRI), Tehran , Jalilian, Amir Reza Radiopharmaceutical Research & Development Laboratory (RRDL) - Nuclear Science and Technology Research Institute (NSTRI), Tehran , Naseri, Zohreh Radiopharmaceutical Research & Development Laboratory (RRDL) - Nuclear Science and Technology Research Institute (NSTRI), Tehran , Yousefnia, Hassan Radiopharmaceutical Research & Development Laboratory (RRDL) - Nuclear Science and Technology Research Institute (NSTRI), Tehran , Bahrami Samani, Ali Radiopharmaceutical Research & Development Laboratory (RRDL) - Nuclear Science and Technology Research Institute (NSTRI), Tehran , Ghannadi-Maragheh, Mohammad Radiopharmaceutical Research & Development Laboratory (RRDL) - Nuclear Science and Technology Research Institute (NSTRI), Tehran , Afarideh, Hossein Faculty of Energy Engineering and Physics - Amirkabir University of Technology, Tehran
Abstract :
Objective(s): In this study, 166Ho-1,2-propylene di-amino tetra(methy1enephosphonicAcid) (166Ho-PDTMP) complex was prepared as a bone palliation agent. Materials and Methods: The complex was successfully prepared using an in-house synthesized EDTMP ligand and 166HoCl3. Ho-166 chloride was obtained by thermal neutron irradiation (1 × 1013 n.cm-2.s-1) of natural Ho(NO3)3 samples followed by radiolabeling and stability studies. Biodistribution in wild type rats was also peformed. Results: The complex was prepared with the specific activity of 278 GBq/mg and high radiochemical purity (>99%, checked by ITLC). 166Ho-PDTMP complex was stabilized in the final preparation and in the presence of human serum (>90%) up to 72 hr. The biodistribution of 166Ho-PDTMP in wild-type rats demonstrated significant bone uptake was up to 48 hr compared to 166HoCl3.
Conclusion: The produced 166Ho-PDTMP properties suggest a possible new bone palliative therapeutic to overcome the metastatic bone pains.
Keywords :
Biodistribution , 166Ho , PDTMP , Radiopharmaceutical , Therapy
